Table 3.
Estimated prevalence of GO and variants of GO. (a) shows prevalence by severity and (b) for clinical variants (all grades of severity)
| PREVALENCE (per 10,000 population) | PROPORTION OF PATIENTS WITH VARIANT | SOURCE | |
|---|---|---|---|
| (a) | |||
| All cases of GO | 8.97 | - | [18] |
| 15.48 | [19, 20] | ||
| Mild GO | 5.83 | 65.0% | [18] |
| 11.03 | 72.8% | [19, 20] | |
| Moderate-to-severe | 2.96–4.45 | 33.0–29.4% | [18–20] |
| Sight-threatening | 0.18 | 2.0% | [11, 14] |
| (b) | |||
| Euthyroid/hypothyroid GO | 0.02–1.10 | 0.2–11.0% | [29–33] |
| GO associated with dermopathy | 0.15 | 1.5% | [7] |
| GO associated with acropachy | 0.03 | 0.3% | [7] |
| Asymmetrical GO | 1.00–5.00 | 10.0–50.0% | [34–36] |
| Unilateral GO | 0.50–1.50 | 5.0–15.0% | [35–38] |